Correspondence 0001493152-25-008385 from Anebulo Pharmaceuticals, Inc. (ANEB) (CIK 0001815974) (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB) (CIK 0001815974)
Date: Feb. 26, 2025 · CIK: 0001815974 · Accession: 0001493152-25-008385
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285098
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Jason Drory Anebulo Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed February 20, 2025 File No: 333-285098
Dear Mr. Drory:
Anebulo Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-285098), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Friday, February 28, 2025, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request for acceleration has been granted.
Very
truly yours,
ANEBULO
PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
February
26, 2025
VIA
EDGAR
United
States Securities
and
Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Jason Drory
Re:
Anebulo
Pharmaceuticals, Inc.
Registration
Statement on Form S-3
Filed
February 20, 2025
File
No: 333-285098
Dear
Mr. Drory:
Anebulo
Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration
Statement on Form S-3 (File No. 333-285098), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Friday, February 28, 2025, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The
Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware
of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration
Statement.
The
Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact
Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify Ms. Marlow when this request
for acceleration has been granted.
Very
truly yours,
ANEBULO
PHARMACEUTICALS, INC.
By:
/s/
Richard A. Cunningham
Name:
Richard
A. Cunningham
Title:
Chief
Executive Officer
cc:
Leslie Marlow, Blank Rome LLP